Nexuspiral is developing ST genome editing technology using only oligonucleotides. Because this technology enables accurate genome editing, application to the treatment of human genetic diseases is expected. We have started research for the development of therapeutic agents for specific diseases. We are looking for research partners on specific diseases.
We are also looking for capital investors.
Naoyuki is a founder and serves as Chief Executive Officer of Nexuspiral, having 20 years of working experience specializing in research and development in pharmaceutical company. His specialty is medicinal chemistry. After graduated from Waseda University Graduate School of Science and Engineering, joined Astellas Pharmaceutical, where he was responsible for the project of psychialitic therapeutics. After that, he was in charge of bussiness creation in academia at Kobe University. Since 2019, he has been in current possition.
Nobuyuki is a senior researcher in Nexuspiral. He is an expert in biology, especially in stem cells. After graduating from Kyoto University, he started his carrier as researcher in Akita University. After that, he worked at the Center for iPS Cell Research and Application and Foundation for Biomedical Researc and Innovation at Kobe for stem cell research. He joined Nexuspiral in 2019.